Rekand T, et al. - Researchers ascertained if botulinum neurotoxin (BoNT) injections that target the neuromuscular junction (NMJ) were non-inferior to current injection practices in terms of effectiveness. In this open-label prospective evaluator-blinded study, findings revealed that the proportion of responders at elbow flexors was 72.7% in the current practice group and 56.8% in the NMJ-targeted group in the intention-to-treat population. Comparable outcomes were noted in the per protocol population. Non-inferiority of NMJ-targeted injections could not be determined due to the limited number of participants, though there was no statistical difference between groups.